We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BIOCIUS and Agilent Launch High-throughput, RapidFire® Accurate Mass Solution for Drug Discovery
Product News

BIOCIUS and Agilent Launch High-throughput, RapidFire® Accurate Mass Solution for Drug Discovery

BIOCIUS and Agilent Launch High-throughput, RapidFire® Accurate Mass Solution for Drug Discovery
Product News

BIOCIUS and Agilent Launch High-throughput, RapidFire® Accurate Mass Solution for Drug Discovery


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BIOCIUS and Agilent Launch High-throughput, RapidFire® Accurate Mass Solution for Drug Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BIOCIUS Life Sciences, Inc. and Agilent Technologies Inc. has announced the launch of the RF360 High Resolution System for high-throughput screening of in vitro ADME assays.

Combining the accurate mass capabilities of Agilent’s time-of-flight (TOF) mass spectrometers and the unprecedented sample processing speed of RapidFire® technology, the instrument revolutionizes in vitro ADME analysis by eliminating the method development bottleneck in drug discovery, the company claims.

The latest addition to the RapidFire portfolio, the RF360 High Resolution system, will be on display in the BIOCIUS hospitality suite at the 58th Annual American Society for Mass Spectrometry Conference in Salt Lake City, Utah from May 23rd to May 27th. “High resolution mass spectrometry coupled with the unparalleled sample preparation throughput of the RapidFire platform enables significant streamlining of in vitro ADME assays,” said Can ‘Jon’ Ozbal, Chief Operating Officer of BIOCIUS. “Extending our partnership with Agilent Technologies, the leader in TOF mass spectrometry allows us to completely eliminate the bottleneck of developing test-compound specific mass spectrometry methods.” This revolutionary approach to in vitro ADME has been demonstrated to reduce analysis time to a fraction of that of conventional methods while requiring a minimal amount of operator input.

RapidFire technology combined with TOF mass spectrometers enables a wide range of ADME assays, including drug-drug interaction, metabolic stability, Caco, PAMPA and others. When performing such assays with the RF360, a priori knowledge of the test compound is not required, as data is acquired in full scan TOF-MS mode. Post acquisition, the relevant data is extracted using RapidFire software, eliminating the time consuming and labor-intensive steps of LC/MS method development and batch analysis.

“Only TOF spectrometry can meet the scan speed and resolution demands required for these high-throughput types of applications,” said Gustavo Salem, vice president and general manager of Agilent’s Biological Systems Division. “Partnering with BIOCIUS on the RF360 has provided a solution that is the fastest approach to ADME on the market.”

Representatives from BIOCIUS and Agilent will be at the ASMS Conference at booth numbers 67 and 68, respectively. The RF360 High Resolution System will be on display in BIOCIUS Hospitality suite, 251A, at the Salt Palace Convention Center. Additionally oral and poster presentations will feature the instrumentation:

ORAL PRESENTATION:

Session: Increasing Throughput for ADME and PK Assays

8:50 a.m., Monday, June 24th, Hall 2

Reducing Bottlenecks in ADME Sample Analysis using Solid Phase Extraction with a Quadrupole Time-of-Flight Mass Spectrometer. Panos Hatsis, Michelle Romm, Vaughn Miller, Jakal Amin, William A. LaMarr, Can “Jon” Ozbal, Shawn Harriman. Novartis Institutes for Biomedical Research, Cambridge, MA; BIOCIUS Lifesciences, Woburn, MA

POSTERS:

1. Session: TP21, Drug Metabolism: High Throughput

Number: 498, Tuesday June 25th

Evaluation of Accurate Mass TOF-MS for Use in High Throughput PAMPA Screening. Michelle Romm, Nikunj Parikh, Vaughn Miller, William A. LaMarr, Can “Jon” Ozbal. BIOCIUS Life Sciences, Inc., Woburn, MA

2. Session: TP21, Drug Metabolism: High Throughput Time

Number: 500, Tuesday June 25th

Comparison of LC/MS/MS and a Fully Integrated Autosampler/Solid Phase Extraction System for the Analysis of Permeability Samples. Adam C Amaral, Christopher Caldwell, Panos Hatsis, Jakal Amin, Shawn Harriman. Novartis, Cambridge, MA

3. Session: ThP24, High Throughput Analysis/Robotics

Number: 572, Thursday, June 27th.

Development of a High-Throughput MS-Based Bioanalytical Method for Assessment of P-Glycoprotein Inhibition Andrew Wagner, Janet Kolb, John Herbst, Tatyana Zvyaga, Conway Charlie, Harold Weller, Wilson Shou, Can “Jon” Ozbal. Bristol-Myers Squibb Company, Wallingford, CT; Bristol-Myers Squibb Company, Princeton, NJ; BIOCIUS Life Sciences, Inc, Woburn, MA.
Advertisement